PCNU and recurrent childhood brain tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1987-10

AUTHORS

Jeffrey C. Allen, Counce Hancock, Russell Walker, Charlotte Tan

ABSTRACT

PCNU, the latest nitrosourea analogue to be subjected to clinical trials, held promise as a superior chemotherapy agent for brain tumors because of more favorable biochemical and cytotoxic characteristics in laboratory studies. Thirty-nine children with a variety of recurrent primary CNS tumors, all of whom had evaluable disease, participated in a phase II PCNU trial. Their mean age was 9.7 (3-20) years. PCNU was administered as a 2 hour intravenous infusion in one of 2 dose schedules at 6-7 week intervals; 100-125 mg/m2 for minimally treated patients and 70-90 mg/m2 for heavily treated patients. Response was assessed after 2 courses of chemotherapy after attempting to taper the steroid dose. The overall objective response rate was 18% (7/39) for a mean of 5.9 months (2+ -12). Only partial responses were observed. Disease-specific responses rates were: brainstem glioma--18% (3/17); cerebral glioma--27% (3/12); ependymoma--1/1; and primitive neuroectodermal tumors--(0/9) including 5 medulloblastomas, 2 pineoblastomas and 3 cerebral primitive neuroectodermal tumors. Toxicity was primarily hematologic and clinically significant thrombocytopenia (less than 50,000 mm3) was encountered in 30/38 (79%) patient trials. Modest activity of PCNU in recurrent childhood gliomas is confirmed. Our response rates, using objective CT criteria, are somewhat lower than those reported for BCNU and CCNU. Because of comparable hematologic toxicity and efficacy, intravenous PCNU does not appear to offer a clinical advantage to existing nitrosoureas for children with recurrent brain tumors using a 2 hour intravenous infusion schedule. More... »

PAGES

241-244

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00151228

DOI

http://dx.doi.org/10.1007/bf00151228

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027240728

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3681386


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkylating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitrosourea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spinal Cord Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, USA", 
            "Departments of Neurology, Memorial Sloan Kettering Cancer Center, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allen", 
        "givenName": "Jeffrey C.", 
        "id": "sg:person.015115640247.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015115640247.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hancock", 
        "givenName": "Counce", 
        "id": "sg:person.0647706075.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647706075.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, USA", 
            "Departments of Neurology, Memorial Sloan Kettering Cancer Center, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walker", 
        "givenName": "Russell", 
        "id": "sg:person.012157434632.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012157434632.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Charlotte", 
        "id": "sg:person.0652334273.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652334273.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00165583", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019258395", 
          "https://doi.org/10.1007/bf00165583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197503)35:3+<965::aid-cncr2820350718>3.0.co;2-#", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042310171"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079794572", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080352269", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081678006", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081934782", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082097891", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1987-10", 
    "datePublishedReg": "1987-10-01", 
    "description": "PCNU, the latest nitrosourea analogue to be subjected to clinical trials, held promise as a superior chemotherapy agent for brain tumors because of more favorable biochemical and cytotoxic characteristics in laboratory studies. Thirty-nine children with a variety of recurrent primary CNS tumors, all of whom had evaluable disease, participated in a phase II PCNU trial. Their mean age was 9.7 (3-20) years. PCNU was administered as a 2 hour intravenous infusion in one of 2 dose schedules at 6-7 week intervals; 100-125 mg/m2 for minimally treated patients and 70-90 mg/m2 for heavily treated patients. Response was assessed after 2 courses of chemotherapy after attempting to taper the steroid dose. The overall objective response rate was 18% (7/39) for a mean of 5.9 months (2+ -12). Only partial responses were observed. Disease-specific responses rates were: brainstem glioma--18% (3/17); cerebral glioma--27% (3/12); ependymoma--1/1; and primitive neuroectodermal tumors--(0/9) including 5 medulloblastomas, 2 pineoblastomas and 3 cerebral primitive neuroectodermal tumors. Toxicity was primarily hematologic and clinically significant thrombocytopenia (less than 50,000 mm3) was encountered in 30/38 (79%) patient trials. Modest activity of PCNU in recurrent childhood gliomas is confirmed. Our response rates, using objective CT criteria, are somewhat lower than those reported for BCNU and CCNU. Because of comparable hematologic toxicity and efficacy, intravenous PCNU does not appear to offer a clinical advantage to existing nitrosoureas for children with recurrent brain tumors using a 2 hour intravenous infusion schedule.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00151228", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435353", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "PCNU and recurrent childhood brain tumors", 
    "pagination": "241-244", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "81c39df588b74f10fe826b086ac82fe4960d101230f82f086c414d0fcca866cc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3681386"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00151228"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027240728"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00151228", 
      "https://app.dimensions.ai/details/publication/pub.1027240728"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130826_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF00151228"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00151228'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00151228'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00151228'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00151228'


 

This table displays all metadata directly associated to this object as RDF triples.

158 TRIPLES      21 PREDICATES      48 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00151228 schema:about N01671620f699486bb733c14c80a41d3d
2 N0a07ccfca354487bb0b1ec104a6f65ae
3 N4d9559bf45434637a255022a6cc15ed0
4 N58acf440cce44815bcf34b37f6602e5f
5 N5f281b28e0e24de9819c0b344ab43a47
6 N971efd1d469a4dde9e6842e9e44572fa
7 N9d15deda54624e498bec017f78588c76
8 Na0857f8b799345a0ba85bdcc6d7e1917
9 Na6138b5220914c16a4ee8f7422539cf5
10 Nb7018b74cb184cb493deca15fdee5c1e
11 Nbf582d544f7b45e39c04ef85521c9fe4
12 Nc4b635d7a1384ccf8580e9ac2be11bb2
13 anzsrc-for:11
14 anzsrc-for:1109
15 schema:author N66a20f701b1142dc99086b09dd8debfe
16 schema:citation sg:pub.10.1007/bf00165583
17 https://app.dimensions.ai/details/publication/pub.1079794572
18 https://app.dimensions.ai/details/publication/pub.1080352269
19 https://app.dimensions.ai/details/publication/pub.1081678006
20 https://app.dimensions.ai/details/publication/pub.1081934782
21 https://app.dimensions.ai/details/publication/pub.1082097891
22 https://doi.org/10.1002/1097-0142(197503)35:3+<965::aid-cncr2820350718>3.0.co;2-#
23 schema:datePublished 1987-10
24 schema:datePublishedReg 1987-10-01
25 schema:description PCNU, the latest nitrosourea analogue to be subjected to clinical trials, held promise as a superior chemotherapy agent for brain tumors because of more favorable biochemical and cytotoxic characteristics in laboratory studies. Thirty-nine children with a variety of recurrent primary CNS tumors, all of whom had evaluable disease, participated in a phase II PCNU trial. Their mean age was 9.7 (3-20) years. PCNU was administered as a 2 hour intravenous infusion in one of 2 dose schedules at 6-7 week intervals; 100-125 mg/m2 for minimally treated patients and 70-90 mg/m2 for heavily treated patients. Response was assessed after 2 courses of chemotherapy after attempting to taper the steroid dose. The overall objective response rate was 18% (7/39) for a mean of 5.9 months (2+ -12). Only partial responses were observed. Disease-specific responses rates were: brainstem glioma--18% (3/17); cerebral glioma--27% (3/12); ependymoma--1/1; and primitive neuroectodermal tumors--(0/9) including 5 medulloblastomas, 2 pineoblastomas and 3 cerebral primitive neuroectodermal tumors. Toxicity was primarily hematologic and clinically significant thrombocytopenia (less than 50,000 mm3) was encountered in 30/38 (79%) patient trials. Modest activity of PCNU in recurrent childhood gliomas is confirmed. Our response rates, using objective CT criteria, are somewhat lower than those reported for BCNU and CCNU. Because of comparable hematologic toxicity and efficacy, intravenous PCNU does not appear to offer a clinical advantage to existing nitrosoureas for children with recurrent brain tumors using a 2 hour intravenous infusion schedule.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N0465daa0a0624528bfa9457e0c2a6a1c
30 Ncd3ba6cb3efe4e45b7fc42bec8513fcd
31 sg:journal.1094205
32 schema:name PCNU and recurrent childhood brain tumors
33 schema:pagination 241-244
34 schema:productId N0c7ab9ffd71842b195f94624484eda4d
35 N711308971bb34aa8801527cfe4c678f4
36 N9c4a2e6b5f4946de96d2c7ad3d2ae183
37 Nb23e0ee6d6c94a3986af6136d55c4490
38 Ned30c6ae83bd4f1f91ca272f9c353554
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027240728
40 https://doi.org/10.1007/bf00151228
41 schema:sdDatePublished 2019-04-11T13:59
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher N4c7ba2e06d58458498d660d199247bdd
44 schema:url http://link.springer.com/10.1007%2FBF00151228
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N01671620f699486bb733c14c80a41d3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
49 schema:name Child
50 rdf:type schema:DefinedTerm
51 N0465daa0a0624528bfa9457e0c2a6a1c schema:volumeNumber 5
52 rdf:type schema:PublicationVolume
53 N0a07ccfca354487bb0b1ec104a6f65ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Child, Preschool
55 rdf:type schema:DefinedTerm
56 N0c7ab9ffd71842b195f94624484eda4d schema:name doi
57 schema:value 10.1007/bf00151228
58 rdf:type schema:PropertyValue
59 N164f08344ed242c9925b2454cd9e1249 rdf:first sg:person.0652334273.10
60 rdf:rest rdf:nil
61 N4c7ba2e06d58458498d660d199247bdd schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 N4d9559bf45434637a255022a6cc15ed0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Humans
65 rdf:type schema:DefinedTerm
66 N5289a8a5265942bc9a75e232f13242b5 rdf:first sg:person.012157434632.04
67 rdf:rest N164f08344ed242c9925b2454cd9e1249
68 N58acf440cce44815bcf34b37f6602e5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Antineoplastic Agents
70 rdf:type schema:DefinedTerm
71 N5f281b28e0e24de9819c0b344ab43a47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Adolescent
73 rdf:type schema:DefinedTerm
74 N66a20f701b1142dc99086b09dd8debfe rdf:first sg:person.015115640247.43
75 rdf:rest N77277437f3c54404b4f28c97b40a1d93
76 N711308971bb34aa8801527cfe4c678f4 schema:name nlm_unique_id
77 schema:value 8309335
78 rdf:type schema:PropertyValue
79 N77277437f3c54404b4f28c97b40a1d93 rdf:first sg:person.0647706075.02
80 rdf:rest N5289a8a5265942bc9a75e232f13242b5
81 N971efd1d469a4dde9e6842e9e44572fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Nitrosourea Compounds
83 rdf:type schema:DefinedTerm
84 N9c4a2e6b5f4946de96d2c7ad3d2ae183 schema:name readcube_id
85 schema:value 81c39df588b74f10fe826b086ac82fe4960d101230f82f086c414d0fcca866cc
86 rdf:type schema:PropertyValue
87 N9d15deda54624e498bec017f78588c76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Drug Evaluation
89 rdf:type schema:DefinedTerm
90 Na0857f8b799345a0ba85bdcc6d7e1917 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Alkylating Agents
92 rdf:type schema:DefinedTerm
93 Na6138b5220914c16a4ee8f7422539cf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Female
95 rdf:type schema:DefinedTerm
96 Nb23e0ee6d6c94a3986af6136d55c4490 schema:name dimensions_id
97 schema:value pub.1027240728
98 rdf:type schema:PropertyValue
99 Nb7018b74cb184cb493deca15fdee5c1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Brain Neoplasms
101 rdf:type schema:DefinedTerm
102 Nbf582d544f7b45e39c04ef85521c9fe4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 Nc4b635d7a1384ccf8580e9ac2be11bb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Spinal Cord Neoplasms
107 rdf:type schema:DefinedTerm
108 Ncd3ba6cb3efe4e45b7fc42bec8513fcd schema:issueNumber 3
109 rdf:type schema:PublicationIssue
110 Ned30c6ae83bd4f1f91ca272f9c353554 schema:name pubmed_id
111 schema:value 3681386
112 rdf:type schema:PropertyValue
113 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
114 schema:name Medical and Health Sciences
115 rdf:type schema:DefinedTerm
116 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
117 schema:name Neurosciences
118 rdf:type schema:DefinedTerm
119 sg:grant.2435353 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00151228
120 rdf:type schema:MonetaryGrant
121 sg:journal.1094205 schema:issn 0167-594X
122 1573-7373
123 schema:name Journal of Neuro-Oncology
124 rdf:type schema:Periodical
125 sg:person.012157434632.04 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
126 schema:familyName Walker
127 schema:givenName Russell
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012157434632.04
129 rdf:type schema:Person
130 sg:person.015115640247.43 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
131 schema:familyName Allen
132 schema:givenName Jeffrey C.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015115640247.43
134 rdf:type schema:Person
135 sg:person.0647706075.02 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
136 schema:familyName Hancock
137 schema:givenName Counce
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647706075.02
139 rdf:type schema:Person
140 sg:person.0652334273.10 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
141 schema:familyName Tan
142 schema:givenName Charlotte
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652334273.10
144 rdf:type schema:Person
145 sg:pub.10.1007/bf00165583 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019258395
146 https://doi.org/10.1007/bf00165583
147 rdf:type schema:CreativeWork
148 https://app.dimensions.ai/details/publication/pub.1079794572 schema:CreativeWork
149 https://app.dimensions.ai/details/publication/pub.1080352269 schema:CreativeWork
150 https://app.dimensions.ai/details/publication/pub.1081678006 schema:CreativeWork
151 https://app.dimensions.ai/details/publication/pub.1081934782 schema:CreativeWork
152 https://app.dimensions.ai/details/publication/pub.1082097891 schema:CreativeWork
153 https://doi.org/10.1002/1097-0142(197503)35:3+<965::aid-cncr2820350718>3.0.co;2-# schema:sameAs https://app.dimensions.ai/details/publication/pub.1042310171
154 rdf:type schema:CreativeWork
155 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
156 schema:name Departments of Neurology, Memorial Sloan Kettering Cancer Center, NY, USA
157 Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, NY, USA
158 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...